Search results for "Fibrin"

showing 10 items of 508 documents

Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets.

2006

Platelet activation causes conformational changes of integrin GPIIb/IIIa (α IIb β 3 ), resulting in the exposure of its ligand-binding pocket. This provides the unique possibility to design agents that specifically block activated platelets only. We used phage display of single-chain antibody (scFv) libraries in combination with several rounds of depletion/selection to obtain human scFvs that bind specifically to the activated conformation of GPIIb/IIIa. Functional evaluation of these scFv clones revealed that fibrinogen binding to human platelets and platelet aggregation can be effectively inhibited by activation-specific scFvs. In contrast to clinically used GPIIb/IIIa blockers, which ar…

Blood PlateletsCarotid Artery DiseasesBleeding TimePhysiologyAmino Acid MotifsMolecular ConformationEptifibatidePlatelet Glycoprotein GPIIb-IIIa ComplexFerric CompoundsAntibodiesMiceChloridesFibrinolytic AgentsmedicineAbciximabAnimalsHumansPlateletPlatelet activationChemistryFibrinogen bindingFibrinogenThrombosisTirofibanPlatelet ActivationMolecular biologyComplementarity Determining RegionsMice Inbred C57BLTirofibanImmunologyEptifibatidePlatelet aggregation inhibitorTyrosineCardiology and Cardiovascular MedicineGlycoprotein IIb/IIIaPeptidesPlatelet Aggregation Inhibitorsmedicine.drugCirculation research
researchProduct

One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.

2006

Aim. Statins are the drugs of choice in heterozygous familial hypercholesterolemia (FH), which has a high risk of premature cardiovascular events including myocardial infarction, stroke, and surgical revascularization. Methods. A 1-year open-label study was conducted to test the efficacy and tolerability of Atorvastatin titrated to the target, in proven FH patients and to evaluate certain inflammatory parameters. One hundred and two FH patients (44 men and 58 women; mean age 58.7±3.6 years) were included in the study. After evaluation using the B-mode duplex scanning system of extracranial carotid arteries, the patients were divided into groups: Group 1 (15 men, 25 women) with carotid plaqu…

Blood PlateletsCarotid Artery DiseasesMaleTime FactorsCarotid Artery CommonHyperlipoproteinemia Type IIAtorvastatinHumansPyrrolesTriglyceridesApolipoproteins BApolipoprotein A-IAnticholesteremic AgentsCholesterol HDLFibrinogenCholesterol LDLMiddle Agedhs-CRPC-Reactive ProteinTreatment OutcomeHeptanoic AcidsPatient ComplianceFemaleHeterozygous familial hypercholesterolemiaHydroxymethylglutaryl-CoA Reductase InhibitorsCarotid arteryInternational angiology : a journal of the International Union of Angiology
researchProduct

Leukocyte–platelet aggregates—a phenotypic characterization of different stages of peripheral arterial disease

2016

The formation of monocyte-platelet aggregates and neutrophil-platelet aggregates (MPA and NPA, respectively) is influenced by inflammation, but also might contribute to an exacerbation of inflammatory responses in atherosclerotic plaque. The purpose of this study was to analyze MPA and NPA proportions in regard to different stages of peripheral arterial disease (PAD). Forty-five patients with intermittent claudication (IC) (3 groups: Rutherford (R)-1, R-2, and R-3; each n = 15), 20 patients with critical limb ischemia (CLI) (Rutherford 5 (40%) and 6 (60%)), and 20 healthy controls were studied. Analyses of monocyte (Mon) subpopulations (CD14++CD16- (classical) Mon1, CD14++CD16+ (intermediat…

Blood PlateletsMale0301 basic medicinemedicine.medical_specialtyNeutrophilsLipopolysaccharide ReceptorsInflammationComorbidity030204 cardiovascular system & hematologyFibrinogenMonocytesProinflammatory cytokinePeripheral Arterial Disease03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineLeukocytesmedicineHumansPlateletReceptors ImmunologicAgedCell AggregationWhole bloodAged 80 and overbusiness.industryMonocyteReceptors IgGHematologyGeneral MedicineCritical limb ischemiaMiddle AgedFlow CytometryIntermittent claudicationBlood Cell CountPhenotype030104 developmental biologyEndocrinologymedicine.anatomical_structureImmunologyFemalemedicine.symptombusinessCell Adhesion MoleculesBiomarkersmedicine.drugPlatelets
researchProduct

The mechanisms of thrombotic risk induced by hormone replacement therapy.

2001

Abstract Objective : To review the available information on the action of hormones on the mechanisms involved in thrombotic risk. Results and Conclusions : Thrombosis plays a crucial role in the genesis and progression of both coronary heart disease (CHD) and venous thromboembolic disease (VTED), the two main forms of cardiovascular disease. Two main determinants of the thromboembolic phenotype, hypercoagulable state and altered endothelium, accumulate much of the work performed on the influence of hormones on thrombosis. Information has accumulated mainly for oestrogens, but increasing evidences support a role for progestogens. The sensitivity of each of the three components of the hemosta…

Blood PlateletsMalemedicine.medical_specialtyArteriosclerosismedicine.medical_treatmentCoronary DiseaseDiseaseBioinformaticsFibrinogenGeneral Biochemistry Genetics and Molecular Biologychemistry.chemical_compoundRisk FactorsInternal medicineFibrinolysismedicineHumansHormone replacement therapyEndothelial dysfunctionAgedVenous ThrombosisHemostasisFactor VIIbusiness.industryAntithrombinEstrogen Replacement TherapyObstetrics and GynecologyEstrogensMiddle Agedmedicine.diseasePostmenopauseEndocrinologyPhenotypechemistryHemostasisFemaleEndothelium Vascularbusinessmedicine.drugMaturitas
researchProduct

A peptide from the staphylococcal protein Efb binds P‐selectin and inhibits the interaction of platelets with leukocytes

2022

AimsP-selectin is a key surface adhesion molecule for the interaction of platelets with leukocytes. We have shown previously that the N-terminal domain of S. aureus extracellular fibrinogen-binding protein (Efb) binds to P-selectin and interferes with platelet-leukocyte aggregate formation. Here, we aimed to identify the minimal Efb motif required for binding platelets and to characterise its ability to interfering with the formation of platelet-leukocyte aggregates.Methods and ResultsUsing a library of synthetic peptides, we mapped the platelet-binding site to a continuous 20 amino acid stretch. The peptide Efb68-87 was able to bind to resting and, to a greater extent, thrombin-stimulated …

Blood PlateletsP-selectinPeptide030204 cardiovascular system & hematologyFibrinogenplatelet-leukocyte aggregate03 medical and health sciences/dk/atira/pure/subjectarea/asjc/2700/27200302 clinical medicineLeukocytesExtracellularmedicineHumansPlateletPlatelet activation030304 developmental biologyplateletInflammationchemistry.chemical_classification0303 health sciencesneutrophil extracellular trapChemistryFibrinogenThrombosisHematologyNeutrophil extracellular trapsPlatelet ActivationCell biologyP-SelectinthromboinflammationP-selectinPeptidesGlycoproteinleukocytemedicine.drugJournal of Thrombosis and Haemostasis
researchProduct

Platelets Contribution to Thrombin Generation in Philadelphia-Negative Myeloproliferative Neoplasms: The "Circulating Wound" Model.

2021

Current cytoreductive and antithrombotic strategies in MPNs are mostly based on cell counts and on patient’s demographic and clinical history. Despite the numerous studies conducted on platelet function and on the role of plasma factors, an accurate and reliable method to dynamically quantify the hypercoagulability states of these conditions is not yet part of clinical practice. Starting from our experience, and after having sifted through the literature, we propose an in-depth narrative report on the contribution of the clonal platelets of MPNs—rich in tissue factor (TF)—in promoting a perpetual procoagulant mechanism. The whole process results in an unbalanced generation of thrombin and i…

Blood PlateletsQH301-705.5platelet functionMPNInflammationReviewDiseaseBioinformaticsFibrinogenModels BiologicalCatalysisPAR receptorLeukemia Myeloid Chronic Atypical BCR-ABL NegativeInorganic ChemistryTissue factorThrombinAntithromboticmedicineAnimalsHumansThrombophiliaPlateletPhysical and Theoretical ChemistryBiology (General)Molecular BiologyQD1-999SpectroscopyPAR receptorsbusiness.industryOrganic ChemistryThrombinGeneral MedicineComputer Science ApplicationsChemistryReceptors FibrinogenCoagulationthrombin generationBiological Assayfibrinogenmedicine.symptombusinessmedicine.drugInternational journal of molecular sciences
researchProduct

Targeted SERPIN (TaSER): A dual‐action antithrombotic agent that targets platelets for SERPIN delivery

2021

BACKGROUND Occlusive thrombi are not homogeneous in composition. The core of a thrombus is rich in activated platelets and fibrin while the outer shell contains resting platelets. This core is inaccessible to plasma proteins. We produced a fusion protein (targeted SERPIN-TaSER), consisting of a function-blocking VH H against glycoprotein Ibα (GPIbα) and a thrombin-inhibiting serine protease inhibitor (SERPIN; α1-antitrypsin 355 AIAR358 ) to interfere with platelet-driven thrombin formation. AIM To evaluate the antithrombotic properties of TaSER. METHODS Besides TaSER, we generated three analogous control variants with either a wild-type antitrypsin subunit, a non-targeting control VH H, or …

Blood PlateletsbiologyChemistryHematologySerpinFibrinCell biologyTissue factorPlatelet AdhesivenessThrombinFibrinolytic AgentsVon Willebrand factorvon Willebrand FactorAntithromboticmedicinebiology.proteinHumansPlateletPlatelet activationSerpinscirculatory and respiratory physiologymedicine.drugJournal of Thrombosis and Haemostasis
researchProduct

Coronary artery disease: Risk stratification and patient selection for more aggressive secondary prevention.

2017

In patients with stable coronary artery disease, clinical outcomes are predominantly characterized by the consequences of atherosclerosis on the myocardium, but also by complications of atherosclerosis, notably recurrent acute coronary syndrome or stroke. Secondary prevention therapy is therefore key in this patient population. Intensification of secondary prevention therapy is possible, at the price of a therapeutic risk or a high cost, therefore justifying careful selection of patients with a high residual risk and low therapeutic risk. Two lines of therapy can be intensified, independently of each other, namely anti-thrombotics and lipid-lowering agents. Intensification of anti-thromboti…

Blood Plateletsmedicine.medical_specialtyAcute coronary syndromeStatinEpidemiologymedicine.drug_classCoronary Artery Disease030204 cardiovascular system & hematologyCoronary artery disease03 medical and health sciences0302 clinical medicineEzetimibeFibrinolytic AgentsRecurrenceRisk FactorsInternal medicineDiabetes mellitusmedicineSecondary PreventionHumans030212 general & internal medicineMyocardial infarctionStrokeBlood CoagulationDyslipidemiasHypolipidemic Agentsbusiness.industryPatient Selectionmedicine.diseaseLipidsResidual riskTreatment OutcomeDisease ProgressionCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugEuropean journal of preventive cardiology
researchProduct

Alternative method to treat oroantral communication and fistula with autogenous bone graft and platelet rich firbin

2016

Background Removing a tooth from the jaw results in the occurrence of oroantral communication in beneficial anatomic conditions or in the case of a iatrogenic effect. Popularized treatments of the oroantral communication have numerous faults. Large bone defect eliminates the chance to introduce an implant. Purpose of this work was assessment of the usefulness of autogenous bone graft and PRF in normal bone regeneration in the site of oroantral communication. Material and Methods Bone regeneration in the site of oroantral communication was assessed in 20 patients. Bone defects were supplemented autogenous bone graft from mental protuberance in 14 cases and from oblique line in 6 cases. The g…

Blood Plateletsmedicine.medical_specialtyBone RegenerationFistulaDentistryFibrin03 medical and health sciences0302 clinical medicinePlatelet-Rich FibrinmedicineHumansOroantral communicationOroantral FistulaBone regenerationGeneral DentistryAlternative methodsFibrinBone Transplantationbiologybusiness.industryResearchAutogenous bone graft030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]Platelet-rich fibrinSurgeryOtorhinolaryngology030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASbiology.proteinSurgeryImplantOral Surgerybusiness
researchProduct

Enhanced platelet thromboxane synthesis and reduced macrophage-dependent fibrinolytic activity related to oxidative stress in oral contraceptive-trea…

1996

Abstract In previous studies conducted in rats and in women, we have shown that oral contraceptive (OC) administration induced a platelet hyperaggregation simultaneously with an increased platelet lipid biosynthesis which might be related to lipid peroxidation. In the present study, we specifically studied the arachidonic acid and the fibrinolytic pathways in relation to the fatty acid composition in female rats treated for 6 weeks with OC (ethinyl estradiol plus lynestrenol). We found that platelets of treated animals were not only hyper-responsive to thrombin and ADP, but also to sodium arachidonate. In addition, the results of the thrombin-induced release of labeled arachidonic acid pre-…

Blood Plateletsmedicine.medical_specialtyErythrocytesPlatelet AggregationThromboxaneRadioimmunoassayLipid peroxidationRats Sprague-Dawleychemistry.chemical_compoundThromboxane A2Internal medicineLipid biosynthesisThromboembolismmedicineAnimalsArachidonic AcidFibrinolysisThromboxanesUrokinase-Type Plasminogen ActivatorRecombinant ProteinsRatsThromboxane B2Disease Models AnimalOxidative StressEndocrinology12-Hydroxyheptadecatrienoic acidchemistryMacrophages Peritoneal12-Hydroxyeicosatetraenoic acidArachidonic acidFemaleLipid PeroxidationCardiology and Cardiovascular MedicineContraceptives OralAtherosclerosis
researchProduct